Amiodarone therapy in chronic heart failure and myocardial infarction: A review of the mortality trials with special attention to STAT-CHF and the GESICA trials

Jr Pinto V., K. Ramani, S. Neelagaru, M. Kown, Mihai Gheorghiade*

*Corresponding author for this work

Research output: Contribution to journalReview article

8 Scopus citations

Abstract

Amiodarone appears to reduce sudden death in patients with left ventricular dysfunction resulting from an acute MI or a primary dilated cardiomyopathy, particularly if complex ventricular arrhythmias are present. Amiodarone's beneficial effect on mortality in these patients could be unrelated to its antiarrhythmic effects. Multiple factors could account for the improvement in mortality such as the drug's anti-ischemic effects, neuremodulating effects, its effect on left ventricular function and on heart rate. Moreover, patients with LV dysfunction who have survived an episode of sudden death would potentially benefit from amiodarone therapy. Future trials are needed to determine the precise subsets(s) of patients who would benefit from the drug and the most efficacious dosing regimen for the drug. Based on available data, amiodarone is the only antiarrhythmic agent which has not been shown to increase mortality in patients with chronic heart failure.

Original languageEnglish (US)
Pages (from-to)85-94
Number of pages10
JournalProgress in Cardiovascular Diseases
Volume40
Issue number1
DOIs
StatePublished - Aug 12 1997

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine

Fingerprint Dive into the research topics of 'Amiodarone therapy in chronic heart failure and myocardial infarction: A review of the mortality trials with special attention to STAT-CHF and the GESICA trials'. Together they form a unique fingerprint.

  • Cite this